CancerNetwork® spoke with James R. Berenson, MD, president and medical director of the Berenson Cancer Center, and founder of the Institute for Myeloma & Bone Cancer Research, about toxicities associated with ruxolitinib (Jakafi) combination therapy, as well as strategies for reducing them. Additionally, the synergistic effects of adding ruxolitinib to selinexor were discussed.
Ruxolitinib Elicits Few Adverse Effects When Treating Multiple Myeloma

All Press
Make an Appointment
Related Articles
[dgbm_blog_module posts_number=”3″ show_thumbnail=”off” show_author=”off” show_pagination=”off” show_more=”on” space_between=”42px” equal_height=”on” container_margin=”||||false|false” container_padding=”||||false|false” article_margin=”||||false|false” article_padding=”||||false|false” content_margin=”||||false|false” content_padding=”30px|30px|30px|30px|true|true” meta_bottom_padding=”||||false|false” button_wrapper_margin=”20px||||false|false” category_location=”top” date_margin=”10px||10px||true|false” module_class=”zdm-blog-grid” _builder_version=”4.21.0″ _module_preset=”default” title_text_color=”#17374E” title_line_height=”1.1em” read_more_font=”||||||||” read_more_text_color=”#009ACA” read_more_font_size=”16px” date_font=”|600|||||||” date_text_color=”#2C6893″ date_font_size=”13px” category_font=”|600||on|||||” category_text_color=”#2C6893″ category_font_size=”13px” category_letter_spacing=”1px” background_color=”#FFFFFF” border_width_all_post_item=”2px” border_color_all_post_item=”gcid-f0845e9b-066a-4b8b-a6b5-20f5259bbdfd” border_style_all_post_item=”dashed” global_colors_info=”{%22gcid-f0845e9b-066a-4b8b-a6b5-20f5259bbdfd%22:%91%22border_color_all_post_item%22%93}” read_more_text_color__hover_enabled=”on|desktop” read_more_text_color__hover=”#16B591″ title_text_color__hover_enabled=”on|desktop” title_text_color__hover=”#2C6893″ category_text_color__hover_enabled=”on|desktop” category_text_color__hover=”#2C6893″][/dgbm_blog_module]